Chinese official press journalist says if Taiwan leader was Catalan she would be in jail
Comparison between China and Spain handling of independence campaigns after Nicaragua's move to end diplomatic ties with Taipei
taiwan
Spain removes Covid entry requirements for US
No longer vaccine certificate or negative test required from those coming from America, Lebanon, Albania, North Macedonia, Serbia and Taiwan
Catalan pharmaceutical giant Grifols sees a 23% jump in net profit in the first half of 2014
During the first half of the year, the revenues of the Catalan multinational pharmaceutical company Grifols rose by 16.7% to €1.61 bilion, 75% of which came from the Bioscience division and 18% from Diagnostic. Compared to the first quarter, the proportion of total sales generated by each of the group’s divisions remains unchanged after the acquisition of Novartis' diagnostic business. The world´s third-largest blood-derivate product maker, Grifols obtained a net profit of €224.8 million, 23% more compared with the same period last year, as reported by the company to the Spanish Stock Exchange Authority (CNMV). These positive figures were achieved due to the maintenance of financial costs, made possible by improved financial conditions, despite having increased debt in absolute terms.
20% increase of Catalan caviar sales produced by Caviar Nacarii, from the Pyrenees
The Catalan brand sold 812 kilograms of caviar in 2012, all being produced in the Vall d’Aran County, in the north-western corner of Catalonia, in the middle of the Pyrenees. The sales increase is due to the growth in the international sales of its product. The 2012 main market has been Russia but now they are trying to introduce its caviar to Sweden and Taiwan. Therefore, they will be present in 10 countries in Europe and Asia. Besides caviar, the company also sold 7.5 tons of sturgeon meat which represents a 7% rise over the previous year.